MXPA05008860A - Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas. - Google Patents

Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.

Info

Publication number
MXPA05008860A
MXPA05008860A MXPA05008860A MXPA05008860A MXPA05008860A MX PA05008860 A MXPA05008860 A MX PA05008860A MX PA05008860 A MXPA05008860 A MX PA05008860A MX PA05008860 A MXPA05008860 A MX PA05008860A MX PA05008860 A MXPA05008860 A MX PA05008860A
Authority
MX
Mexico
Prior art keywords
sphingolipid
methods
present
safingol
same
Prior art date
Application number
MXPA05008860A
Other languages
English (en)
Inventor
Patrick C Reynolds
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of MXPA05008860A publication Critical patent/MXPA05008860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion proporciona soluciones acuosas estables que consisten esencialmente de: (a) un esfingolipido; (b) acido lactico; y (c) opcionalmente un agente estabilizante; en donde la solucion tiene una relacion molar de acido lactico a esfingolipido de 1:1 a 10:1; la presente invencion proporciona ademas una formulacion en emulsion que consiste esencialmente de: (a) acido lactico; (b) un esfingolipido, en donde el esfingolipido esta presente en una cantidad de aproximadamente 0.1 a aproximadamente 30 mg/ml de emulsion; (b) opcionalmente un agente isotonico; y (c) un fosfolipido presente en una cantidad de aproximadamente 0.2 a aproximadamente 200 mg/ml de emulsion; tambien se proporcionan los metodos para hacer y utilizar las composiciones.
MXPA05008860A 2003-02-21 2004-02-19 Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas. MXPA05008860A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44953603P 2003-02-21 2003-02-21
PCT/US2004/004960 WO2004075834A2 (en) 2003-02-21 2004-02-19 Stabilized pharmaceutical compositions of safingol and methods of using the same

Publications (1)

Publication Number Publication Date
MXPA05008860A true MXPA05008860A (es) 2005-10-05

Family

ID=32927531

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008860A MXPA05008860A (es) 2003-02-21 2004-02-19 Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.

Country Status (9)

Country Link
US (1) US7476692B2 (es)
EP (1) EP1594488B1 (es)
JP (2) JP4842800B2 (es)
AT (1) ATE331507T1 (es)
CA (1) CA2516399C (es)
DE (1) DE602004001393T2 (es)
ES (1) ES2270347T3 (es)
MX (1) MXPA05008860A (es)
WO (1) WO2004075834A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709379B2 (en) 2006-03-29 2014-04-29 Scitech Development, Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
CA2817198C (en) * 2009-11-12 2018-05-01 Texas Tech University Compositions and methods for treating hyperproliferative disorders
EP3024441A4 (en) * 2013-07-25 2017-04-19 Nemucore Medical Innovations, Inc. Nanoemulsions of hydrophobic platinum derivative
IT201600105201A1 (it) * 2016-10-19 2018-04-19 Nutrilinea Srl Uso della fosfatidilserina per la prevenzione e il trattamento dei disturbi della prostata e relative composizioni farmaceutiche e nutraceutiche
US10034895B2 (en) * 2017-11-30 2018-07-31 Joel Steven Goldberg Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003028A1 (en) * 1993-07-23 1995-02-02 Morris Herstein Cosmetic, skin-renewal stimulating composition with long-term irritation control
CA2234968A1 (en) * 1995-10-18 1997-04-24 Mary Kay Inc. Topically applied, structural cellulite treatments
US5635536A (en) * 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
CA2335941C (en) * 1998-06-29 2011-03-22 Barry James Maurer Treatment of hyperproliferative disorders
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
JP3220434B2 (ja) * 1998-12-28 2001-10-22 花王株式会社 化粧料
KR100343885B1 (ko) * 1999-07-20 2002-07-19 주식회사 두산 파이토스핑고신의 수용액의 제조 방법
KR100371491B1 (ko) * 1999-07-27 2003-02-07 주식회사 두산 피부 보호용 크림조성물
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP3896234B2 (ja) * 1999-12-24 2007-03-22 花王株式会社 化粧料
EP1287815A1 (en) * 2001-08-31 2003-03-05 Cosmoferm B.V. Use of a sphingoid base for inhibiting ceramidase activity
JP4119646B2 (ja) * 2001-12-10 2008-07-16 花王株式会社 セラミド類乳化物の製造法
JP4220698B2 (ja) * 2001-12-10 2009-02-04 花王株式会社 皮膚外用剤
CN100340227C (zh) * 2001-12-10 2007-10-03 花王株式会社 神经酰胺类乳化物
PT1545619E (pt) * 2002-09-05 2008-02-28 Galderma Sa Solução destinada a uma aplicação sobre as unhas

Also Published As

Publication number Publication date
JP2011126886A (ja) 2011-06-30
ATE331507T1 (de) 2006-07-15
JP4842800B2 (ja) 2011-12-21
DE602004001393T2 (de) 2007-06-14
WO2004075834A2 (en) 2004-09-10
EP1594488B1 (en) 2006-06-28
ES2270347T3 (es) 2007-04-01
CA2516399A1 (en) 2004-09-10
CA2516399C (en) 2013-05-14
US20050187186A1 (en) 2005-08-25
WO2004075834A3 (en) 2005-03-24
JP2006518743A (ja) 2006-08-17
DE602004001393D1 (de) 2006-08-10
US7476692B2 (en) 2009-01-13
EP1594488A2 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
EA200400777A1 (ru) Фармацевтические композиции соединения платины
UA92470C2 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
EA200500891A1 (ru) Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание
UY27320A1 (es) Nuevas composiciones farmacéuticas
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
HUP0400387A2 (hu) A tobramicin aeroszol kialakítására optimalizált készítménye és eljárás az előállítására
MY151470A (en) Controlled release solid preparation
PL357132A1 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation
BRPI0410116A (pt) tablete de cuidado oral
RU2009102803A (ru) Пригодный для инъекции состав антибиотика и раствор для его внутреннего введения
TW200735864A (en) Immediate release pharmaceutical formulation
BR0316724A (pt) Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
MXPA05008860A (es) Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.
JP3146218B2 (ja) 点眼剤
DK1660097T3 (da) Fysiologisk aktiv sammensætning baseret på phosphatidylserin
CA2535533A1 (en) Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline
WO2004095921A3 (en) Sporicidal composition
JP2003517462A5 (es)
CO5021217A1 (es) Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas
AU2003224107A1 (en) Soluble composition containing sporopollenin and the use thereof
TW200505469A (en) Glycyrrhizin containing pharmaceutical composition
KR0159730B1 (ko) 케토코나졸 수성 제제
CA2545880A1 (en) Erythropoietin solution formulation

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration